On September 27, 2023, Law N° 31881 (hereinafter, the Law) was published, which aims to provide information on foods that do not contain gluten on product labels so that consumers, mainly people suffering from celiac disease, intolerance or joy to gluten, can make informed consumption decisions.
The Law establishes that product labels that include references such as “gluten-free” or “gluten-free” must comply with the conditions established in the respective Regulation (it has not yet been approved and the Ministry of Health has a term of 60 calendar days to approve it) and manufacturers must have a good manufacturing practices program established by DIGESA (it has not been approved either). In addition, it is indicated that manufacturers will be able to indicate on the packages, containers, wrappers or labels of products that do not contain gluten, the symbol of a barred ear of corn within a circle, according to the characteristics established in the Regulations of the Law.
The Technical Standard states that the vaccination scheme against Covid-19 administered in the Peruvian territory with monovalent vaccines in the period 2021 until August 2023 refers to the initial vaccination scheme to ensure sufficient initial immune response.
According to the scientific evidence and safety of the vaccine, the number of doses is variable per year, depending on the prioritized group and availability of the vaccine in the country.
The new vaccination schedule is:
Target population Vaccination history Dose N°. with component Application interval with number* the new component
06 months to 4 years 0 doses 02 doses At first contact and 28 days between doses
01 dose applied over 01 doses 03 months or more since last dose
05 months to 59 years 0 dose applied 01 doses At first contact
01 dose applied over 01 doses 03 months or more since last dose
60 years and older 0 dose applied 02 doses At first contact and 28 days between doses
01 dose applied over 02 doses First dose: at 03 months
Second dose**: at 04 months after the first dose.
Specifically, vaccines manufactured by ModernaTX Inc. and Pfizer Inc. have been updated to include a monovalent component that corresponds to the Omicron XBB.1.5 variant.
Law N° 31870 amended Law N° 31336, the National Cancer Law.
The most relevant modifications were:
It is established that the National Policy for the Fight against Cancer or PNC will be conducted by the National Institute of Neoplastic Diseases (INEN).
The intangibility of the Budgetary Program 0024 “Prevention and Control of Cancer” is declared of national interest, and INEN is entrusted as the national technical responsible for the management of this program.
The creation of the National Network of Tumor Banks in charge of the National Institute of Health (INS) in coordination with INEN is established.
